Therefore, cases with these mutations could benefit from PI3K/AKT inhibition, as demonstrated in vascular tumors by studies (Yuksekkaya et al., 2012; Ferrés-Ramis et al., 2015). The gene discussed is AKT1; the disease is vascular neoplasm.